MCID: CCC001
MIFTS: 58

Coccidioidomycosis

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Coccidioidomycosis

MalaCards integrated aliases for Coccidioidomycosis:

Name: Coccidioidomycosis 12 74 52 58 54 3 43 15 17 71 32
Valley Fever 52 58 42 3
Primary Extrapulmonary Coccidioidomycosis 12 71
Coccidiosis 52 71
Primary Pulmonary Coccidioidomycosis 71
Coccidioides Immitis Infection 52
San Joaquin Valley Fever 58
Acute Coccidioidomycosis 71
Coccidioides Infection 58
Enteric Coccidiosis 71
California Disease 58
San Joaquin Fever 52
Desert Rheumatism 58
Desert Fever 58

Characteristics:

Orphanet epidemiological data:

58
coccidioidomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:13450
ICD9CM 34 114
MeSH 43 D003047
NCIt 49 C84642
SNOMED-CT 67 60826002
ICD10 32 B38 B38.9
MESH via Orphanet 44 D003047
UMLS via Orphanet 72 C0009186 C0153257 C0851907
Orphanet 58 ORPHA228123
UMLS 71 C0009186 C0009187 C0153257 more

Summaries for Coccidioidomycosis

MedlinePlus : 42 Valley Fever is a disease caused by a fungus (or mold) called Coccidioides. The fungi live in the soil of dry areas like the southwestern U.S. You get it from inhaling the spores of the fungus. The infection cannot spread from person to person. Anyone can get Valley Fever. But it's most common among older adults, especially those 60 and older. People who have recently moved to an area where it occurs are at highest risk for infection. Other people at higher risk include Workers in jobs that expose them to soil dust. These include construction workers, agricultural workers, and military forces doing field training. African Americans and Asians Women in their third trimester of pregnancy People with weak immune systems Valley Fever is often mild, with no symptoms. If you have symptoms, they may include a flu-like illness, with fever, cough, headache, rash, and muscle aches. Most people get better within several weeks or months. A small number of people may develop a chronic lung or widespread infection. Valley Fever is diagnosed by testing your blood, other body fluids, or tissues. Many people with the acute infection get better without treatment. In some cases, doctors may prescribe antifungal drugs for acute infections. Severe infections require antifungal drugs. Centers for Disease Control and Prevention

MalaCards based summary : Coccidioidomycosis, also known as valley fever, is related to coccidiosis and cryptosporidiosis, and has symptoms including arthritis, chest pain and conjunctivitis. An important gene associated with Coccidioidomycosis is CD69 (CD69 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fluconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and lung, and related phenotypes are hearing impairment and arthritis

Disease Ontology : 12 A primary systemic mycosis that results in systemic fungal infection, has material basis in Coccidioides immitis, transmitted by airborne spores and has symptom conjunctivitis, has symptom arthritis, has symptom chest pain and results in formation of skin nodules.

CDC : 3 Valley fever, also called coccidioidomycosis, is an infection caused by the fungus Coccidioides. The fungus is known to live in the soil in the southwestern United States and parts of Mexico and Central and South America. The fungus was also recently found in south-central Washington. People can get Valley fever by breathing in the microscopic fungal spores from the air, although most people who breathe in the spores don't get sick. Usually, people who get sick with Valley fever will get better on their own within weeks to months, but some people will need antifungal medication. Certain groups of people are at higher risk for becoming severely ill. It's difficult to prevent exposure to Coccidioides in areas where it's common in the environment, but people who are at higher risk for severe Valley fever should try to avoid breathing in large amounts of dust if they're in these areas.

Wikipedia : 74 In medicine, coccidioidomycosis (/kɒkˌsɪdiɔɪdoʊmaɪˈkoʊsɪs/, kok-sid-ee-oy-doh-my-KOH-sis), commonly... more...

Related Diseases for Coccidioidomycosis

Diseases related to Coccidioidomycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 687)
# Related Disease Score Top Affiliating Genes
1 coccidiosis 33.2 TNF TLR4 IL17A CD40LG CD4 CCR6
2 cryptosporidiosis 32.7 MBL2 CD40LG CD4
3 diarrhea 30.7 TNF TLR4 STAT1 CD40LG
4 osteomyelitis 30.7 TNF TLR4 STAT1 IFNGR1
5 yellow fever 30.6 STAT1 IL17A CCR6
6 plague 30.4 TNF TLR4 CD4
7 prosthetic joint infection 30.3 TLR4 MBL2
8 pericarditis 30.3 TNF CD40LG CD4
9 acquired immunodeficiency syndrome 30.2 TNF CD40LG CD4 CCR6
10 genital herpes 30.2 CD40LG CD4 CCR6
11 duodenitis 30.2 TNF CD40LG CD4
12 exanthem 30.1 TNF CD40LG CD4 CCR6
13 granulomatous dermatitis 30.1 TNF CD40LG CD4
14 pelvic inflammatory disease 30.1 TLR4 CD40LG CD4
15 stomatitis 30.1 TNF TLR4 CD40LG CD4
16 toxic shock syndrome 30.1 TNF TLR4 CD40LG
17 peritonitis 30.0 TNF TLR4 IL17A CD69
18 primary syphilis 30.0 CD40LG CD4
19 neuroretinitis 30.0 CD40LG CD4
20 poliomyelitis 29.9 TNF CD40LG CD4
21 paracoccidioidomycosis 29.9 TNF TLR4 IL12RB1 CD40LG
22 cerebritis 29.9 TNF CD40LG CD4
23 meningitis 29.9 TNF TLR4 MBL2 IL17A CD40LG
24 human immunodeficiency virus type 1 29.9 TNF STAT1 CD69 CD4
25 dysentery 29.9 TNF TLR4 CD40LG CD4 CCR6
26 pneumonia 29.8 TNF TLR4 MBL2 IL17A CD40LG
27 respiratory failure 29.8 TNF TLR4 CD40LG CD4 CCR6
28 neutropenia 29.8 TNF TLR4 MBL2 CD40LG
29 brucellosis 29.8 TNF TLR4 IL17A CD40LG
30 vasculitis 29.8 TNF MBL2 IL17A CD40LG
31 bacterial sepsis 29.7 TNF TLR4 CCR6
32 pulmonary sarcoidosis 29.7 TNF IL12RB1 CCR6
33 chorioretinitis 29.7 TNF IL17A CD40LG CD4
34 aspergillosis 29.7 TNF TLR4 MBL2 CLEC7A CCR6
35 phaeohyphomycosis 29.7 CLEC7A CLEC6A CARD9
36 endophthalmitis 29.7 TNF CD4 CARD9
37 granulomatous hepatitis 29.7 TNF CD40LG CD4
38 intestinal disease 29.7 TNF TLR4 IL17A CD4 CCR6
39 guillain-barre syndrome 29.7 TNF CD40LG CCR6
40 lung abscess 29.7 TNF CD40LG CD4
41 salpingitis 29.6 TNF CD40LG CD4
42 herpes zoster 29.6 TNF CD40LG CD4 CCR6
43 lepromatous leprosy 29.6 TNF IL12RB1 IFNGR1
44 sporotrichosis 29.6 MBL2 CLEC7A CD40LG CD4 CARD9
45 bronchiectasis 29.6 TNF STAT1 MBL2
46 mumps 29.6 TNF STAT1 CD69 CD40LG
47 allergic hypersensitivity disease 29.6 TNF IL17A CD69 CD4 CCR6
48 nocardiosis 29.6 TNF IL12RB1 CD4
49 iridocyclitis 29.6 TNF IL17A CD40LG CD4
50 pulmonary tuberculosis 29.5 TNF TLR4 MBL2 IL12RB1 IFNGR1

Graphical network of the top 20 diseases related to Coccidioidomycosis:



Diseases related to Coccidioidomycosis

Symptoms & Phenotypes for Coccidioidomycosis

Human phenotypes related to Coccidioidomycosis:

58 (show top 50) (show all 76)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hearing impairment 58 Very rare (<4-1%)
2 arthritis 58 Occasional (29-5%)
3 seizures 58 Very rare (<4-1%)
4 hydrocephalus 58 Very rare (<4-1%)
5 cognitive impairment 58 Very rare (<4-1%)
6 photophobia 58 Very rare (<4-1%)
7 fatigue 58 Occasional (29-5%)
8 renal insufficiency 58 Very rare (<4-1%)
9 fever 58 Frequent (79-30%)
10 immunodeficiency 58 Frequent (79-30%)
11 broad ribs 58 Very rare (<4-1%)
12 skin rash 58 Occasional (29-5%)
13 pruritus 58 Occasional (29-5%)
14 papule 58 Occasional (29-5%)
15 pericarditis 58 Very rare (<4-1%)
16 pulmonary infiltrates 58 Occasional (29-5%)
17 osteomyelitis 58 Very rare (<4-1%)
18 osteolysis 58 Very rare (<4-1%)
19 myalgia 58 Occasional (29-5%)
20 cough 58 Occasional (29-5%)
21 chest pain 58 Occasional (29-5%)
22 atypical scarring of skin 58 Occasional (29-5%)
23 hemoptysis 58 Occasional (29-5%)
24 abnormality of the bladder 58 Very rare (<4-1%)
25 cerebral ischemia 58 Very rare (<4-1%)
26 abnormality of the kidney 58 Very rare (<4-1%)
27 abnormality of the vertebral column 58 Very rare (<4-1%)
28 vasculitis 58 Very rare (<4-1%)
29 headache 58 Very rare (<4-1%)
30 abnormality of the nervous system 58 Occasional (29-5%)
31 abnormality of the endocrine system 58 Very rare (<4-1%)
32 mediastinal lymphadenopathy 58 Occasional (29-5%)
33 abnormality of the metacarpal bones 58 Very rare (<4-1%)
34 abnormality of the spleen 58 Very rare (<4-1%)
35 abnormality of the liver 58 Very rare (<4-1%)
36 lymphadenopathy 58 Occasional (29-5%)
37 eosinophilia 58 Occasional (29-5%)
38 respiratory distress 58 Occasional (29-5%)
39 pneumonia 58 Frequent (79-30%)
40 abnormality of the genitourinary system 58 Very rare (<4-1%)
41 abnormality of long bone morphology 58 Very rare (<4-1%)
42 abnormality of blood and blood-forming tissues 58 Very rare (<4-1%)
43 pancreatitis 58 Very rare (<4-1%)
44 peritonitis 58 Very rare (<4-1%)
45 abnormality of the male genitalia 58 Very rare (<4-1%)
46 abscess 58 Occasional (29-5%)
47 panniculitis 58 Occasional (29-5%)
48 personality changes 58 Very rare (<4-1%)
49 broad metatarsal 58 Very rare (<4-1%)
50 abnormality of the female genitalia 58 Very rare (<4-1%)

Symptoms:

12
  • arthritis
  • chest pain
  • conjunctivitis

UMLS symptoms related to Coccidioidomycosis:


fever, pruritus

MGI Mouse Phenotypes related to Coccidioidomycosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 CARD9 CCR6 CD4 CD40LG CD69 CLEC6A
2 homeostasis/metabolism MP:0005376 10.07 CARD9 CCR6 CD4 CD40LG CLEC7A CYP51A1
3 immune system MP:0005387 10.03 CARD9 CCR6 CD4 CD40LG CD69 CLEC6A
4 digestive/alimentary MP:0005381 9.97 CD4 CLEC7A CYP51A1 IFNGR1 IL17A STAT1
5 integument MP:0010771 9.56 CD4 CD40LG IFNGR1 IL12RB1 IL17A STAT1
6 skeleton MP:0005390 9.28 CD40LG CD69 CYP51A1 IFNGR1 IL17A MBL2

Drugs & Therapeutics for Coccidioidomycosis

Drugs for Coccidioidomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4 Cytochrome P-450 Enzyme Inhibitors Phase 4
5 Anti-Infective Agents Phase 4
6 Hormone Antagonists Phase 4
7 Hormones Phase 4
8 Antifungal Agents Phase 4
9
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
10
Itraconazole Approved, Investigational Phase 2, Phase 3 84625-61-6 55283
11 Antiprotozoal Agents Phase 3
12 Antiparasitic Agents Phase 3
13 Anti-Infective Agents, Local Phase 3
14 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
15
Hydroxyitraconazole Phase 2, Phase 3
16 Vaccines Phase 2
17 Nikkomycin Phase 1, Phase 2
18
Methotrexate Approved 59-05-2, 1959-05-2 126941

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever) Terminated NCT02663674 Phase 4 Fluconazole
2 Safety, Sensitivity and Specificity of Spherule-derived Coccidioidin in Naive Adults, in Adults With a History of Pulmonary Coccidioidomycosis and in Adults With a History of Pulmonary Histoplasmosis Completed NCT00690092 Phase 3
3 A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis Completed NCT00423267 Phase 3 Posaconazole;Fluconazole
4 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
5 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
6 SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial Recruiting NCT03572049 Phase 2, Phase 3 SUBA itraconazole;Conventional itraconazole
7 Parts A&B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study Completed NCT00584194 Phase 2
8 Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study Completed NCT00415051 Phase 2
9 Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years Completed NCT00307021 Phase 2
10 A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region. Completed NCT00289185 Phase 2
11 A Phase 2 Open Label Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated, Dried, TSI-GSD 200, Lot 7, Run 2, in Adult Subjects at Risk of Exposure to Rift Valley Fever Virus Recruiting NCT03609398 Phase 2
12 Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults Active, not recruiting NCT00869713 Phase 2
13 Phase I/II Evaluation of the Safety, Pharmacokinetics, and Preliminary Effectiveness of Nikkomycin Z in the Treatment of Patients With Uncomplicated Coccidioides Pneumonia Terminated NCT00614666 Phase 1, Phase 2 nikkomycin Z
14 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Withdrawn NCT02908334 Phase 2 Sertraline
15 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
16 A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of VT-1598 in Healthy Adult Subjects Recruiting NCT04208321 Phase 1 VT-1598
17 Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis Completed NCT00796809
18 Late Outcomes of Rift Valley Fever in Kenya: Ijara Clinical Survey Completed NCT00287014
19 A Double-Blind, Placebo-Controlled Study of Fluconazole in the Prevention of Active Coccidioidomycosis and Other Systemic Fungal Infections in HIV-Infected Patients Living in the Coccidioidal Endemic Area Completed NCT00002325 Fluconazole
20 Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis Completed NCT00002010 Fluconazole
21 Organ Transplant Infection Prevention and Detection Project 1.0; Cohort Study of Transplant Recipients at "Ultra-High" Risk for Invasive Fungal Infections Completed NCT00177801
22 An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC) Recruiting NCT03908632
23 The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis Recruiting NCT02190266
24 Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment Active, not recruiting NCT03618992
25 Study of Patients With Parasitic Infections of the Gastrointestinal Tract Terminated NCT00001162

Search NIH Clinical Center for Coccidioidomycosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fluconazole
Itraconazole
Ketoconazole

Cochrane evidence based reviews: coccidioidomycosis

Genetic Tests for Coccidioidomycosis

Anatomical Context for Coccidioidomycosis

MalaCards organs/tissues related to Coccidioidomycosis:

40
Testes, Skin, Lung, Bone, Liver, T Cells, Prostate

Publications for Coccidioidomycosis

Articles related to Coccidioidomycosis:

(show top 50) (show all 4311)
# Title Authors PMID Year
1
Coccidioidomycosis (Valley Fever) in Primary Care. 42 61
32053327 2020
2
What You Should Know About Valley Fever. 61 42
32053335 2020
3
Population Structure and Genetic Diversity among Isolates of Coccidioides posadasii in Venezuela and Surrounding Regions. 42 61
31772050 2019
4
In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K. 61 54
12204956 2002
5
Disseminated coccidioidomycosis: Monitoring of serologic markers for treatment response. 61
32551217 2020
6
Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. 61
32337506 2020
7
Transboundary Animal Diseases (TADs) affecting domestic and wild African ungulates: African swine fever, foot and mouth disease, Rift Valley fever (1996-2018). 61
32311588 2020
8
First serological evidence of the Rift Valley fever Phlebovirus in Tunisian camels. 61
32325049 2020
9
Risk for Coccidioidomycosis among Hispanic Farm Workers, California, USA, 2018. 61
32568046 2020
10
The V1016G mutation of the voltage-gated sodium channel (VGSC) gene contributes to the insecticide resistance of Aedes aegypti from Makassar, Indonesia. 61
32458116 2020
11
Risk factors and outcomes of culture-proven acute Coccidioides spp. infection in San Diego, California, United States. 61
32176829 2020
12
The detection of Coccidioides from ambient air in Phoenix, Arizona: Evidence of uneven distribution and seasonality. 61
31506673 2020
13
Simultaneous Coccidioidomycosis and Phaeohyphomycosis in a Kidney Transplant Recipient: A Case Report and Literature Review. 61
32533741 2020
14
Clinician Practice Patterns that Result in the Diagnosis of Coccidioidomycosis Before or During Hospitalization. 61
32511677 2020
15
Risk assessment for the Rift Valley fever occurrence in China: Special concern in southwest border areas. 61
32568445 2020
16
Rift Valley Fever: Important Considerations for Risk Mitigation and Future Outbreaks. 61
32498264 2020
17
Rift Valley fever in northern Senegal: A modelling approach to analyse the processes underlying virus circulation recurrence. 61
32479505 2020
18
Disseminated Coccidioidomycosis Treated with Interferon-γ and Dupilumab. 61
32521134 2020
19
Primary Cutaneous Coccidioidomycosis: An Update. 61
32557380 2020
20
Coccidioidomycosis in Patients Treated With Ruxolitinib. 61
32548203 2020
21
Coccidioidomycosis Presenting with Fever and Back Pain. 61
32185657 2020
22
Effect of Environmental Temperature on the Ability of Culex tarsalis and Aedes taeniorhynchus (Diptera: Culicidae) to Transmit Rift Valley Fever Virus. 61
32017863 2020
23
A genome-wide CRISPR-Cas9 screen reveals the requirement of host cell sulfation for Schmallenberg virus infection. 61
32522852 2020
24
Mobile Laboratory Reveals the Circulation of Dengue Virus Serotype I of Asian Origin in Medina Gounass (Guediawaye), Senegal. 61
32560073 2020
25
CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine against Coccidioides posadasii Infection. 61
32358020 2020
26
Shunt Treatment for Coccidioidomycosis-Related Hydrocephalus: A Single-Center Series. 61
32247798 2020
27
Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series. 61
32572997 2020
28
Genomic characterization of Parengyodontium americanum sp. nov. 61
32028048 2020
29
Genetic dissection of Rift Valley fever pathogenesis: Rvfs2 locus on mouse chromosome 11 enables survival to early-onset hepatitis. 61
32457349 2020
30
Comparative analysis of codon usage patterns in Rift Valley fever virus. 61
32422647 2020
31
A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus. 61
32233501 2020
32
Reagents for detection of Rift Valley fever virus infection in sheep. 61
32450762 2020
33
Early Pathogenesis of Wesselsbron Disease in Pregnant Ewes. 61
32414152 2020
34
Neutralizing antibodies against Rift Valley fever virus in wild antelope in far northern KwaZulu-Natal, South Africa, indicate recent virus circulation. 61
31943795 2020
35
Relative Distribution, Diversity, and Bloodmeal Sources of Mosquitoes and Known Vectors of Rift Valley Fever Phlebovirus in Three Differing Ecosystems in Bura, Tana River County, Kenya. 61
31990632 2020
36
Mapping livestock movements in Sahelian Africa. 61
32433590 2020
37
Bicavitary eosinophilic effusion in a dog with coccidioidomycosis. 61
32447816 2020
38
Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening. 61
32284379 2020
39
The Cytocidal Spectrum of Bacillus thuringiensis Toxins: From Insects to Human Cancer Cells. 61
32384723 2020
40
Investigation of Vector-Borne Viruses in Ticks, Mosquitos, and Ruminants in the Thrace District of Turkey. 61
32397953 2020
41
Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia. 61
32354764 2020
42
Evaluation of a commercially available, point-of-care Coccidioides antibody lateral flow assay to aid in rapid diagnosis of coccidioidomycosis in dogs. 61
31212311 2020
43
Antibiotic and antifungal treatment among persons with confirmed coccidioidomycosis - Southern California, 2011. 61
31290546 2020
44
Comparison of three anti-coccidioides antibody enzyme immunoassay kits for the diagnosis of coccidioidomycosis. 61
32277825 2020
45
Rift Valley Fever Outbreak, Mayotte, France, 2018-2019. 61
32186500 2020
46
Microencapsulated plasmids expressing Gn and Gc glycoproteins of Rift Valley Fever virus enhance humoral immune response in mice. 61
31983039 2020
47
Treatment for Early, Uncomplicated Coccidioidomycosis: What Is Success? 61
31544210 2020
48
Identification and RNAi Profile of a Novel Iflavirus Infecting Senegalese Aedes vexans arabiensis Mosquitoes. 61
32295109 2020
49
Sero-Epidemiological Study of Selected Zoonotic and Abortifacient Pathogens in Cattle at a Wildlife-Livestock Interface in South Africa. 61
31841655 2020
50
Identification of Bunyamwera and Possible Other Orthobunyavirus Infections and Disease in Cattle during a Rift Valley Fever Outbreak in Rwanda in 2018. 61
32314686 2020

Variations for Coccidioidomycosis

Expression for Coccidioidomycosis

Search GEO for disease gene expression data for Coccidioidomycosis.

Pathways for Coccidioidomycosis

Pathways related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 TNF TLR4 STAT1 MBL2 IL17A IL12RB1
2
Show member pathways
13.25 TNF STAT1 IL17A IL12RB1 IFNGR1 CD40LG
3
Show member pathways
13.23 TNF TLR4 STAT1 IL17A IL12RB1 CD40LG
4
Show member pathways
12.74 TNF STAT1 IL17A CD40LG CD4
5
Show member pathways
12.53 TNF IL12RB1 IFNGR1 CD40LG CD4
6
Show member pathways
12.52 TNF STAT1 IFNGR1 CD40LG CD4
7
Show member pathways
12.44 TNF STAT1 IL17A IL12RB1 CD4
8 12.41 TNF STAT1 IL17A CD40LG CARD9
9
Show member pathways
12.34 TNF TLR4 STAT1 IL17A IFNGR1 CD40LG
10
Show member pathways
12.24 TNF TLR4 STAT1 IL17A IL12RB1 IFNGR1
11
Show member pathways
12.2 TNF TLR4 STAT1 IFNGR1
12 12.14 TNF TLR4 STAT1 CARD9
13
Show member pathways
12.13 TNF TLR4 STAT1 IFNGR1 CD40LG
14
Show member pathways
12.09 TNF TLR4 STAT1 IFNGR1
15 12.07 TNF TLR4 STAT1 IFNGR1
16
Show member pathways
12.07 TNF STAT1 CLEC7A CLEC6A CARD9
17
Show member pathways
12.05 TNF TLR4 STAT1 IFNGR1
18 11.82 TNF TLR4 CD40LG
19 11.8 TNF TLR4 CD4
20 11.76 TNF TLR4 IL17A
21
Show member pathways
11.76 TLR4 IL17A IL12RB1
22
Show member pathways
11.73 TLR4 STAT1 IL17A IL12RB1 CD4
23 11.69 TNF TLR4 STAT1 IFNGR1 CLEC7A CARD9
24 11.62 TNF IL17A IL12RB1 CD4 CCR6
25 11.44 TNF TLR4 CD40LG
26
Show member pathways
11.19 TNF TLR4 STAT1 IL17A IL12RB1 IFNGR1

GO Terms for Coccidioidomycosis

Cellular components related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 TNF TLR4 IFNGR1 CD69 CD40LG CD4
2 cell surface GO:0009986 9.56 TNF TLR4 MBL2 CLEC7A CD69 CD40LG
3 external side of plasma membrane GO:0009897 9.23 TNF TLR4 IL17A IL12RB1 CD69 CD40LG

Biological processes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.05 TLR4 MBL2 CLEC7A CLEC6A CD4 CARD9
2 innate immune response GO:0045087 10.03 TLR4 MBL2 CLEC7A CLEC6A CARD9
3 inflammatory response GO:0006954 9.95 TNF TLR4 IL17A CLEC7A CD40LG
4 immune response GO:0006955 9.91 TNF TLR4 IL17A CD40LG CD4 CCR6
5 cellular response to interferon-gamma GO:0071346 9.8 TLR4 STAT1 IL12RB1
6 positive regulation of JNK cascade GO:0046330 9.77 TNF TLR4 CARD9
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.77 TNF TLR4 CLEC6A CD4 CARD9
8 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.76 TNF TLR4 CARD9
9 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.74 TNF CLEC7A CARD9
10 positive regulation of interleukin-6 production GO:0032755 9.73 TNF TLR4 CARD9
11 positive regulation of phagocytosis GO:0050766 9.7 TNF MBL2 CLEC7A
12 positive regulation of interferon-gamma production GO:0032729 9.69 TNF TLR4 IL12RB1
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 TNF TLR4 CLEC7A
14 positive regulation of interleukin-6 secretion GO:2000778 9.65 TNF TLR4 IL17A
15 cytokine-mediated signaling pathway GO:0019221 9.63 TNF STAT1 IL17A IL12RB1 IFNGR1 CD4
16 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.62 CLEC7A CD4
17 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.62 STAT1 IFNGR1
18 positive regulation of interferon-alpha production GO:0032727 9.61 TLR4 STAT1
19 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.61 TNF TLR4
20 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.59 TNF IL17A
21 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.58 TLR4 IL17A CLEC7A
22 regulation of immunoglobulin secretion GO:0051023 9.54 TNF CD40LG
23 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.5 TNF TLR4 CLEC7A
24 detection of fungus GO:0016046 9.46 TLR4 CLEC7A
25 negative regulation of amyloid-beta clearance GO:1900222 9.43 TNF IFNGR1 CYP51A1
26 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.13 TLR4 IL17A CLEC7A
27 positive regulation of cytokine production involved in inflammatory response GO:1900017 8.92 TNF TLR4 IL17A CLEC7A

Molecular functions related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.26 MBL2 CLEC7A CLEC6A CD69
2 tumor necrosis factor receptor binding GO:0005164 8.8 TNF STAT1 CD40LG

Sources for Coccidioidomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....